Printer Friendly

SPECTRASCIENCE REPORTS THIRD QUARTER RESULTS

 SPECTRASCIENCE REPORTS THIRD QUARTER RESULTS
 MINNEAPOLIS, Nov. 6 /PRNewswire/ -- SpectraScience, Inc.


(NASDAQ: SPSC), formerly GV Medical, today announced revenue of $73,627 for its third quarter ended Sept. 30, 1992. This compares with revenue of $313,646 for the same period a year ago. The company reported a loss for the quarter of $894,441, relatively unchanged from a loss of $874,724 in the 1991 third quarter. Loss per share for the quarter was 10 cents, compared to 17 cents a year ago.
 The company announced last month that it was focusing its development and commercialization efforts on a new laser-enhanced diagnostic system for vascular disease, and had entered into an agreement with the Cleveland Clinic Foundation for clinical trials of the system.
 SpectraScience Inc.
 (formerly GV Medical, Inc.)
 Third Quarter Financial Data
 3 months ended 9 months ended
 Sept. 30, Sept. 30, Sept. 30, Sept. 30,
 1992 1991 1992 1991
 Revenue $73,627 $313,646 $250,969 $816,401
 Cost of products sold (985) 213,771 80,990 494,624
 Expenses:
 Research and
 development 592,507 536,248 1,645,133 1,789,939
 Selling, general and
 administrative 322,237 465,668 1,503,655 1,502,031
 Less interest and other
 (income) expense 54,309 (18,317) (144,670) (221,105)
 Total expenses 969,053 974,599 3,004,116 3,070,865
 Net loss $(894,441) $(874,724)$(2,834,137)$(2,749,088)
 Net loss per share $(.10) $(.17) $(0.32) $(.53)
 Weighted Average
 Common Shares 9,261,001 5,223,405 8,771,866 5,208,853
 -0- 11/6/92
 /CONTACT: John Swenson of Swenson Falker Eilertsen, 612-371-0000, for SpectraScience; or Tom Ahmann of SpectraScience, 612-559-4000/
 (SPSC) CO: SpectraScience, Inc. ST: Minnesota IN: MTC SU: ERN


AL -- MN014 -- 8366 11/06/92 18:11 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 6, 1992
Words:302
Previous Article:AMERICAN STOCK EXCHANGE DAILY REPORT
Next Article:L.A. AREA GOVERNMENTS TO PAY $45.9 MILLION FOR POLLUTING L.A. COASTLINE
Topics:


Related Articles
SPECTRASCIENCE REPORTS LOSS FOR 1992
SPECTRASCIENCE REPORTS FIRST QUARTER RESULTS, CLINICAL PROGRESS
SPECTRASCIENCE REPORTS REDUCED LOSS FOR THIRD QUARTER
SPECTRASCIENCE REPORTS REDUCED LOSS FOR FOURTH QUARTER AND 1993 YEAR
SpectraScience Files Annual Report for Three Years on 10-KSB.
Annual Report for Three Years on 10-KSB Filed by SpectraScience.
SpectraScience Files Quarterly Report on Form 10-QSB.
Quarterly Report for First Quarter on 10-QSB Filed by SpectraScience.
SpectraScience Receives Patent Notification.
SpectraScience Receives Facility Approval From the FDA.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters